

BILD2

Bilirubin Direct Gen.2 (Dumas standardization)

Order information

REF	CONTENT	Analyzer(s) on which kit(s) can be used
05589037 119	Direct bilirubin Gen.2 ([1] 4 x 66 mL, [2] 4 x 16 mL)	Roche/Hitachi MODULAR P
10759350 360	Calibrator f.a.s. (12 x 3 mL)	Code 401
10171743 160	Precinorm U (20 x 5 mL)	Code 300
10171735 160	Precinorm U (4 x 5 mL)	Code 300
10171778 122	Precipath U (20 x 5 mL)	Code 301
10171760 122	Precipath U (4 x 5 mL)	Code 301
12149435 122	Precinorm U plus (10 x 3 mL)	Code 300
12149443 122	Precipath U plus (10 x 3 mL)	Code 301
05117003 190	PreciControl ClinChem Multi 1 (20 x 5 mL)	Code 391
05947626 190	PreciControl ClinChem Multi 1 (4 x 5 mL)	Code 391
05117216 190	PreciControl ClinChem Multi 2 (20 x 5 mL)	Code 392
05947774 190	PreciControl ClinChem Multi 2 (4 x 5 mL)	Code 392
10158046 122	Precibil (4 x 2 mL)	Code 306

Some analyzers and kits shown may not be available in all countries. For additional system applications, contact your local Roche Diagnostics representative.

English

System information

For Roche/Hitachi MODULAR P analyzers: ACN 727.

Intended use

For the in vitro quantitative determination of direct bilirubin in serum and plasma on Roche automated clinical chemistry analyzers.

Summary¹

Bilirubin is formed in the reticuloendothelial system during the degradation of aged erythrocytes. The heme portion from hemoglobin and from other heme-containing proteins is removed, metabolized to bilirubin, and transported as a complex with serum albumin to the liver. In the liver, bilirubin is conjugated with glucuronic acid for solubilization and subsequent transport through the bile duct and elimination via the digestive tract. Diseases or conditions which, through hemolytic processes, produce bilirubin faster than the liver can metabolize it, cause the levels of unconjugated (indirect) bilirubin to increase in the circulation. Liver immaturity and several other diseases in which the bilirubin conjugation mechanism is impaired cause similar elevations of circulating unconjugated bilirubin. Bile duct obstruction or damage to hepatocellular structure causes increases in the levels of both conjugated (direct) and unconjugated (indirect) bilirubin in the circulation.

Test principle

Diazo method.²

Conjugated bilirubin and δ -bilirubin (direct bilirubin) react directly with 3,5-Dichlorophenyl diazonium salt in acid buffer to form the red-colored azobilirubin.



The color intensity of the red azo dye formed is directly proportional to the direct (conjugated) bilirubin concentration and can be determined photometrically.

Remark: Under the influence of blue light, e.g. during phototherapy of newborn children, unconjugated bilirubin is partly transformed into a water-soluble isomer called photobilirubin, a substrate for direct bilirubin tests. This fraction is detected by BILD2 and may lead to above-normal results in healthy children.

Reagents - working solutions

R1 Phosphoric acid: 85 mmol/L; HEDTA: 4.0 mmol/L; NaCl: 50 mmol/L; detergent; pH 1.9

R2 3,5-Dichlorophenyl diazonium: 1.5 mmol/L; pH 1.3

Precautions and warnings

For in vitro diagnostic use.

Exercise the normal precautions required for handling all laboratory reagents.

Disposal of all waste material should be in accordance with local guidelines. Safety data sheet available for professional user on request.

This kit contains components classified as follows in accordance with the Regulation (EC) No. 1272/2008:



Danger

H314 Causes severe skin burns and eye damage.

Prevention:

P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.

Response:

P301 + P330 IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. + P331

P303 + P361 IF ON SKIN (or hair): Take off immediately all contaminated clothing. Rinse skin with water/shower. + P353

P304 + P340 IF INHALED: Remove person to fresh air and keep comfortable for breathing. Immediately call a POISON CENTER or doctor/physician.

P305 + P351 IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. Immediately call a POISON CENTER or doctor/physician.

Disposal:

P501 Dispose of contents/container to an approved waste disposal plant.

Product safety labeling primarily follows EU GHS guidance. Contact phone: all countries: +49-621-7590

Reagent handling

Ready for use

Storage and stability

Unopened kit components: up to the expiration date at 2-8 °C

R1/R2: 6 weeks opened and refrigerated on the analyzer

Bilirubin Direct Gen.2 (Doumas standardization)

Specimen collection and preparation

For specimen collection and preparation only use suitable tubes or collection containers.

Only the specimens listed below were tested and found acceptable.

Serum: Collect serum using standard sampling tubes.

Plasma: Li-heparin, K₂-, K₃-EDTA plasma.

Store samples protected from light.

The sample types listed were tested with a selection of sample collection tubes that were commercially available at the time of testing, i.e. not all available tubes of all manufacturers were tested. Sample collection systems from various manufacturers may contain differing materials which could affect the test results in some cases. When processing samples in primary tubes (sample collection systems), follow the instructions of the tube manufacturer.

Centrifuge samples containing precipitates before performing the assay.

Stability: ^{a),3,4}	2 days	at 20-25 °C
	7 days	at 4-8 °C
	6 months	at -20 °C

a) If care is taken to prevent exposure to light

Materials provided

See "Reagents – working solutions" section for reagents.

Materials required (but not provided)

- See "Order information" section
- 0.9 % NaCl
- General laboratory equipment

Assay

For optimum performance of the assay follow the directions given in this document for the analyzer concerned. Refer to the appropriate operator's manual for analyzer-specific assay instructions.

The performance of applications not validated by Roche is not warranted and must be defined by the user.

Calibration

Traceability: This method has been standardized against the manual test performance using the Doumas method.⁵

S1: 0.9 % NaCl

S2: C.f.a.s.

Calibration frequency

2-point calibration is recommended:

- after reagent lot change
- as required following quality control procedures.

Quality control

For quality control, use control materials as listed in the "Order information" section.

In addition, other suitable control material can be used.

The control intervals and limits should be adapted to each laboratory's individual requirements. Values obtained should fall within the defined limits. Each laboratory should establish corrective measures to be taken if values fall outside the defined limits.

Follow the applicable government regulations and local guidelines for quality control.

Calculation

The analyzer automatically calculates the analyte concentration of each sample.

Conversion factors: $\mu\text{mol/L} \times 0.0585 = \text{mg/dL}$
 $\text{mg/dL} \times 10 = \text{mg/L}$
 $\text{mg/dL} \times 17.1 = \mu\text{mol/L}$

Limitations - interference

Criterion: Recovery within $\pm 10\%$ of initial values at a direct bilirubin concentration of $34.2 \mu\text{mol/L}$ (2.0 mg/dL).

Hemolysis:⁶ No significant interference up to an H index of 25 (approximate hemoglobin concentration: $15.5 \mu\text{mol/L}$ or 25 mg/dL).

Lipemia (Intralipid):⁶ No significant interference up to an L index of 750. There is poor correlation between the L index (corresponds to turbidity) and triglycerides concentration.

Drugs: No interference was found at therapeutic concentrations using common drug panels.^{7,8}

Exception: Phenylbutazone causes artificially low bilirubin results.

Samples containing indocyanine green must not be measured.

In very rare cases, gammopathy, in particular type IgM (Waldenström's macroglobulinemia), may cause unreliable results.⁹

For diagnostic purposes, the results should always be assessed in conjunction with the patient's medical history, clinical examination and other findings.

In certain cases specimens may give a direct bilirubin result slightly greater than the total bilirubin result. This is observed in patient samples when nearly all the reacting bilirubin is in the direct form. In such cases the result for the total bilirubin should be reported for both direct bilirubin and total bilirubin values.

ACTION REQUIRED

Special Wash Programming: The use of special wash steps is mandatory when certain test combinations are run together on Roche/Hitachi analyzers. Refer to the latest version of the carry-over evasion lists and the operator's manual for further instructions. US users refer to the Special Wash Programming document, available at usdiagnostics.roche.com, and the operator's manual for special wash instructions.

Where required, special wash/carry-over evasion programming must be implemented prior to reporting results with this test.

Limits and ranges

Measuring range

$1.2\text{-}236 \mu\text{mol/L}$ ($0.07\text{-}13.8 \text{ mg/dL}$)

Determine samples having higher concentrations via the rerun function.

Dilution of samples via the rerun function is a 1:2 dilution. Results from samples diluted using the rerun function are automatically multiplied by a factor of 2.

Lower limits of measurement

Limit of Blank, Limit of Detection and Limit of Quantitation

Limit of Blank = $0.8 \mu\text{mol/L}$ (0.05 mg/dL)

Limit of Detection = $1.2 \mu\text{mol/L}$ (0.07 mg/dL)

Limit of Quantitation = $1.2 \mu\text{mol/L}$ (0.07 mg/dL)

The Limit of Blank, Limit of Detection and Limit of Quantitation were determined in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP17-A2 requirements.

The Limit of Blank is the 95th percentile value from $n \geq 60$ measurements of analyte-free samples over several independent series. The Limit of Blank corresponds to the concentration below which analyte-free samples are found with a probability of 95 %.

The Limit of Detection is determined based on the Limit of Blank and the standard deviation of low concentration samples.

The Limit of Detection corresponds to the lowest analyte concentration which can be detected (value above the Limit of Blank with a probability of 95 %).

The Limit of Quantitation is the lowest analyte concentration that can be reproducibly measured with a total error of 20 %. It has been determined using low concentration bilirubin samples.

Values below the Limit of Quantitation will not be flagged by the instrument.

Expected values

Direct bilirubin $\leq 3.4 \mu\text{mol/L}$ ($\leq 0.20 \text{ mg/dL}$)¹

An upper limit of $10 \mu\text{mol/L}$ (0.59 mg/dL) direct Bilirubin for neonates has been cited in the literature, although this has not been confirmed by internal data.¹⁰

Each laboratory should investigate the transferability of the expected values to its own patient population and if necessary determine its own reference ranges.

Bilirubin Direct Gen.2 (Doumas standardization)

Specific performance data

Representative performance data on the analyzers are given below. Results obtained in individual laboratories may differ.

Precision

Precision was determined using human samples and controls in accordance with the CLSI (Clinical and Laboratory Standards Institute) EP5 requirements with repeatability (n = 21) and intermediate precision (2 aliquots per run, 2 runs per day, 21 days). The following results were obtained:

Repeatability					
Sample	Mean		SD		CV
	µmol/L	mg/dL	µmol/L	mg/dL	%
Precinorm U	13.4	0.78	0.1	0.01	0.7
Precipath U	32.9	1.9	0.2	0.01	0.6
Human serum 1	1.8	0.10	0.0	0.00	1.9
Human serum 2	66.9	3.9	0.3	0.02	0.4
Human serum 3	215	12.6	1.2	0.07	0.5

Intermediate precision					
Sample	Mean		SD		CV
	µmol/L	mg/dL	µmol/L	mg/dL	%
Precinorm U	12.0	0.70	0.3	0.02	2.6
Precipath U	31.4	1.8	0.4	0.02	1.4
Human serum 1	1.5	0.09	0.2	0.01	10
Human serum 2	145	8.5	2.1	0.12	1.5
Human serum 3	211	12.3	3.2	0.19	1.5

Results for intermediate precision were obtained on the master system **cobas c 501** analyzer.

Method comparison

A comparison of the Roche BILD2 reagent (y) against the previous Roche DBIL reagent (x) on the Roche/Hitachi MODULAR P analyzer gave the following correlation (µmol/L):

Passing/Bablok ¹¹	Linear regression
$y = 1.013x + 0.44 \mu\text{mol/L}$	$y = 1.007x + 0.63 \mu\text{mol/L}$
$r = 0.939$	$r = 0.996$

Number of samples measured: 67

The sample concentrations were between 1.9 and 132 µmol/L (0.11 and 7.7 mg/dL).

References

- Balistreri WF, Shaw LM. Liver function. In: Tietz NW, ed. Fundamentals of Clinical Chemistry. 3rd ed. Philadelphia: WB Saunders 1987;729-761.
- Malloy HT, Evelyn KA. The determination of bilirubin with the photoelectric colorimeter. J Biol Chem 1937;119:481-490.
- Quality of Diagnostic Samples, Recommendations of the Working Group on Preanalytical Quality of the German Society for Clinical Chemistry and Laboratory Medicine, 3rd completely revised ed. 2010.
- WHO Publication: Use of anticoagulants in diagnostic laboratory investigations, WHO/DIL/LAB/99.1 Rev.2:Jan 2002.
- Doumas BT, Perry BW, Jendrzyszczak B, et al. Pitfalls in the American Monitor Kit Methods for Determination of Total and Direct Bilirubin. Clin Chem 1982;28(11):2305-2308.
- Glick MR, Ryder KW, Jackson SA. Graphical Comparisons of Interferences in Clinical Chemistry Instrumentation. Clin Chem 1986;32:470-475.
- Breuer J. Report on the Symposium "Drug Effects in Clinical Chemistry Methods". Eur J Clin Chem Clin Biochem 1996;34:385-386.

- Sonntag O, Scholer A. Drug interference in clinical chemistry: recommendation of drugs and their concentrations to be used in drug interference studies. Ann Clin Biochem 2001;38:376-385.
- Bakker AJ, Mücke M. Gammopathy interference in clinical chemistry assays: mechanisms, detection and prevention. Clin Chem Lab Med 2007;45(9):1240-1243.
- Soldin JS, Brugnara C, Wong EC. Pediatric Reference Intervals. AACC Press. 2005, 5th ed., p. 42.
- Bablok W, Passing H, Bender R, et al. A general regression procedure for method transformation. Application of linear regression procedures for method comparison studies in clinical chemistry, Part III. J Clin Chem Clin Biochem 1988 Nov;26(11):783-790.

Instrument settings

Users of MODULAR analyzers: Enter the application parameters via the barcode sheet.

For further information, please refer to the appropriate operator's manual for the analyzer concerned, the respective application sheets and method sheets of all necessary components.

A point (period/stop) is always used in this Method Sheet as the decimal separator to mark the border between the integral and the fractional parts of a decimal numeral. Separators for thousands are not used.

Symbols

Roche Diagnostics uses the following symbols and signs in addition to those listed in the ISO 15223-1 standard:

	Contents of kit
	Reagent
	Calibrator
	Volume after reconstitution or mixing
	Global Trade Item Number

COBAS, COBAS C, PRECIBIL, PRECICONTROL, PRECINORM and PRECIPATH are trademarks of Roche.

All other product names and trademarks are the property of their respective owners.

Additions, deletions or changes are indicated by a change bar in the margin.

© 2016, Roche Diagnostics



Roche Diagnostics GmbH, Sandhofer Strasse 116, D-68305 Mannheim
www.roche.com



Note

Please note that the catalogue number appearing on the package insert retains only the first 8 digits of the licensed 11-digit Catalogue Number: 05589037119 for the Bilirubin Direct Gen 2. The last 3 digits -190 have been replaced by -119 for logistic purposes.